Scientists around the world are working faster to develop and develop vaccines that could halt the spread of COVID-19, many of which are now being distributed worldwide. Here is a glimpse of those vaccines and the recent development of people to be tested in clinical trials.Globally, there are now 137 COVID-19 vaccines undergoing clinical trials and 194 on pre-treatment development.An oral vaccine developed by DreamTec Research Limited, a Hong Kong-based biotechnology company, has completed a study that found the technology team to be successful in engineering Bacillus subtilis with spore coat proteins such as nucleus proteins and coronal virus spikes. This product may have a vaccine function within the intestinal tract. This is one of the first examples of a bacterial vector vaccine.
PROTEIN SUBUNIT VACCINE
Taiwanese vaccine maker Medigen has produced a two-dose vaccine made from a combination of spike protein and adjuvant from Dynavax. The company began testing phase 2 for adults in late January 2021. In July, phase 2 testing began for 12- to 18-year-olds. That same month, the 3rd phase of the trial was approved in Paraguay. On July 19, the vaccine was approved for emergency use in Taiwan. October 2021 to measure anti-SARS-CoV-2 blocking antibody titers in adult participants to demonstrate the protection and safety of a third booster booster with Medigen’s COVID-19 vaccine.
